|Mr. Geoffrey Hulme||Interim Principal Exec. Officer||419.64k||N/A||1967|
|Ms. Marianne Zhen CPA||Chief Accounting Officer||673.29k||N/A||1969|
|Mr. Jeffrey A. Hagenah Ph.D.||Chief Patent Counsel and VP||N/A||N/A||N/A|
|Dr. Kevin Kwok||Head of Talent Acquisition & Strategy||N/A||N/A||N/A|
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate (FF); ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Brisbane, California.
Innoviva, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 2. The pillar scores are Audit: 2; Board: 1; Shareholder Rights: 4; Compensation: 5.